PerioTrap Pharmaceuticals

PerioTrap Pharmaceuticals is a German biotechnology company dedicated to developing a novel class of selective anti-infectives for the treatment of chronic inflammatory diseases, with a primary focus on periodontitis. The company's proprietary technology targets a specific bacterial enzyme, glutaminyl cyclase, which is essential for the virulence and survival of key periodontal pathogens like Porphyromonas gingivalis. Unlike broad-spectrum antibiotics, PerioTrap's approach aims to selectively eliminate disease-causing bacteria while preserving the protective oral microbiome. Their lead program is designed for local application within the periodontal pocket to restore oral health and prevent systemic complications associated with gum disease.